Followers | 137 |
Posts | 10050 |
Boards Moderated | 0 |
Alias Born | 04/13/2007 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, January 04, 2020 1:14:11 PM
Other groups are putting their focus on degenerative disc disease, a common condition that can lead to near-constant and debilitating pain (5), and specifically on using cell therapy to rebuild the intervertebral disc material (nucleus pulposus) that serves as a shock absorber between the individual vertebra.
One of the companies with significant research in this area is BioRestorative Therapies of Melville, New York, which is growing and expanding stem cells from the patient’s bone marrow, but doing so under hypoxic conditions that mimic those in the normal intervertebral space (6). “So basically we are enriching the cells to be able to survive in this harsh environment,” said Francisco Silva, the company’s chief scientist and vice president of research and development (Figure 3). The researchers combine the cells with platelet lysate, a blood component that is rich in growth factors and nutrients for the cells, and cryopreserve the final cell product, which they call BRTX-100.
“Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution, and that’s it,” he described. The stem cells function in a couple of different ways. “Stem cells by nature are anti-inflammatory (and) release factors to block the inflammation process,” he explained. The company’s initial animal study showed increased disc height following treatment (Figure 4). Another animal study is planned to examine BRTX-100’s mechanism of action, and to measure changes in pain level following treatment.
The FDA authorized BioRestorative Therapies to initiate a phase 2 clinical trial of the BRTX-100 cell product, which will provide for the study of 99 patients.
Figure 3. Francisco Silva, chief scientist and vice president of research and development for BioRestorative Therapies of Melville, New York, which is developing a cell-therapy product called BRTX-100 to rebuild intervertebral disc material
Figure 4. Silva examines a rabbit disc treated with BRTX-100 (inset). The company’s initial animal study demonstrated increased disc height following treatment. Images courtesy of BioRestorative Therapies.
Besides the BRTX-100 cell product, the company is also pursuing an additional cell-therapy project: utilizing brown adipose (fat) derived stem cells for therapeutic purposes. Since brown adipose tissue expends energy (as opposed to white adipose tissue, which stores it), the company’s goal is to develop an implantable brown adipose tissue construct, which it hopes to use for the treatment of metabolic diseases and disorders, such as type 2 diabetes, obesity and hypertension. The company is working in collaboration with the University of Pennsylvania to research brown adipose biology and its role in metabolic disorders and has also retained the University of Utah to provide research services for this program.
https://pulse.embs.org/november-2019/stem-cell-therapies-low-back-pain/
BRTX
Recent BRTX News
- BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/27/2024 11:40:00 AM
- BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 06/17/2024 11:05:00 AM
- Shares of Biotech MicroCap Rip on Licensing Talks • AllPennyStocks.com • 06/13/2024 03:40:00 PM
- BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/11/2024 08:28:30 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:23:50 PM
- BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 12:50:00 PM
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice • GlobeNewswire Inc. • 05/24/2024 11:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:51:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:45:27 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:17:17 PM
- BioRestorative Therapies Provides First Quarter 2024 Business Update • GlobeNewswire Inc. • 05/14/2024 08:10:00 PM
- BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Biotech Catches Major Premarket Bid Following FDA Clearance • AllPennyStocks.com • 04/16/2024 02:25:00 PM
- BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment • GlobeNewswire Inc. • 04/16/2024 11:45:00 AM
- BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 04/08/2024 11:45:00 AM
- BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants • GlobeNewswire Inc. • 04/03/2024 08:38:00 PM
- BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K • GlobeNewswire Inc. • 04/01/2024 11:45:00 AM
- BioRestorative Therapies to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/11/2024 08:15:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:34:22 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:43:54 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:40:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:27:34 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM